(4-(dimethylamino)phenyl)(pyridin-3-yl)methanone | 42374-78-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-(dimethylamino)phenyl)(pyridin-3-yl)methanone
• 英文别名: (4-dimethylaminophenyl)(pyrid-3-yl)methanone；(4-(Dimethylamino)phenyl)(pyridin-3-yl)methanone；[4-(dimethylamino)phenyl]-pyridin-3-ylmethanone
• CAS: 42374-78-7
• 化学式: C₁₄H₁₄N₂O
• 分子量: 226.278
• InChiKey: UPVFEKUUOIGBAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  对溴三氟甲苯 、 (4-(dimethylamino)phenyl)(pyridin-3-yl)methanone 在 正丁基锂 作用下， 以 乙醚 、 正己烷 、 四氢呋喃 为溶剂， 反应 2.0h， 以73%的产率得到(4-trifluoromethylphenyl)(4-dimethylaminophenyl)pyrid-3-yl methanol
  参考文献：
  名称：

  Analogues of Fenarimol Are Potent Inhibitors of Trypanosoma cruzi and Are Efficacious in a Murine Model of Chagas Disease

  摘要：

  We report the discovery of nontoxic fungicide fenarimol (1) as an inhibitor of Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, and the results of structure-activity investigations leading to potent analogues with low nM IC(50)s in a T. cruzi whole cell in vitro assay. Lead compounds suppressed blood parasitemia to virtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection. Compounds are chemically tractable, allowing rapid optimization of target biological activity and drug characteristics. Chemical and biological studies undertaken in the development of the fenarimol series toward the goal of delivering a new drug candidate for Chagas disease are reported.

  DOI：

  10.1021/jm2015809
• 作为产物：
  描述：

  4-二甲氨基苯甲酸 在 正丁基锂 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 (4-(dimethylamino)phenyl)(pyridin-3-yl)methanone
  参考文献：
  名称：

  Analogues of Fenarimol Are Potent Inhibitors of Trypanosoma cruzi and Are Efficacious in a Murine Model of Chagas Disease

  摘要：

  We report the discovery of nontoxic fungicide fenarimol (1) as an inhibitor of Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, and the results of structure-activity investigations leading to potent analogues with low nM IC(50)s in a T. cruzi whole cell in vitro assay. Lead compounds suppressed blood parasitemia to virtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection. Compounds are chemically tractable, allowing rapid optimization of target biological activity and drug characteristics. Chemical and biological studies undertaken in the development of the fenarimol series toward the goal of delivering a new drug candidate for Chagas disease are reported.

  DOI：

  10.1021/jm2015809

文献信息

• METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20140107094A1

  公开（公告）日：2014-04-17

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括以下式的化合物：其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。该发明还包括一种治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还包括通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。
• Methylene linked quinolinyl modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US09290476B2

  公开（公告）日：2016-03-22

  The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及式I的化合物，其中：R1，R2，R3，R4，R5，R6，R7，R8和R9在说明书中有定义。本发明还涉及一种治疗或改善综合征、疾病或疾患的方法，所述综合征、疾病或疾患是类风湿性关节炎或银屑病。本发明还涉及通过给予至少一种权利要求1中的化合物的治疗有效量来调节哺乳动物中的RORγt活性的方法。
• EP2909192A1
  申请人：——

  公开号：EP2909192A1

  公开（公告）日：2015-08-26
• METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T
  申请人：Janssen Pharmaceutica NV

  公开号：EP2909192B1

  公开（公告）日：2017-05-17
• US9290476B2
  申请人：——

  公开号：US9290476B2

  公开（公告）日：2016-03-22